Big tech, chips, software, cloud, AI platforms, devices, and the companies shaping the digital economy.
A Yahoo Finance report says Alphabet’s aggressive artificial intelligence spending has pushed it into negative free cash flow for the first time, prompting additional borrowing even as the company invests heavily in data centers and AI infrastructure.
THE APEX TIMES
THE APEX TIMES
A Yahoo Finance market note points investors to AlphaSpace statistics to gauge whether Intel’s recent trading strength is more than a brief bounce.
THE APEX TIMES
In a new conversation with Meta executives, the company outlines the reasons it designs and operates custom data centers rather than relying on third-party capacity, framing the choice as part of its preparation for the next phase of AI.
THE APEX TIMES
The film, directed by David O. Russell, follows Madden’s path from Super Bowl-winning coach to the creator and inspiration behind the video game icon.
THE APEX TIMES
A new market column frames how hedge-fund founder Kenneth Griffin tends to think about risk-reward in megacap technology, and applies that lens to three widely owned names: Tesla, Nvidia and Meta.
THE APEX TIMES
A recent stock-prediction note tied to Microsoft’s latest Azure results has Citi raising its price target to $600, a call that other forecasting tools have reportedly aligned with as the market gauges momentum in Microsoft’s cloud business.
THE APEX TIMES
In its second-quarter 2026 letter, Bronte Capital’s Amalthea Fund highlighted Alphabet’s (GOOGL) role in what it calls the AI frontier, alongside reported fund performance.
THE APEX TIMES
Yahoo Finance reports Amazon has raised its capital-expenditure target beyond $220 billion, with AWS demand still accelerating. Investors are weighing whether the spending curve helps Amazon defend cloud infrastructure and pricing, or whether it risks margin pressure before utilization catches up.
THE APEX TIMES
Amazon Pharmacy is advertising steep discounts on weight-loss drug prescriptions for Medicare beneficiaries, intensifying competition with pharmacy chains and large retailers as demand grows for obesity and diabetes-linked therapies.
